CanSino Biologics, Inc. Class H (HK:6185)
:6185
Want to see HK:6185 full AI Analyst Report?
Top Page
CanSino Biologics, Inc. Class H
(6185)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$25.00
▼(-44.37% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial quality (thin/unstable profitability and negative free cash flow) and a bearish technical setup (price below key moving averages with negative MACD). A relatively solid balance sheet with moderate leverage provides some support, but negative earnings (negative P/E) and lack of dividend data limit valuation comfort.
Positive Factors
Moderate leverage and solid balance sheet
A moderate debt-to-equity (~0.26) and a sizeable equity base provide durable financial flexibility. That leverage profile lowers refinancing and interest risk, helping the company fund vaccine R&D, maintain production capacity and absorb demand swings without immediate recourse to dilutive financing.
Negative Factors
Persistent negative free cash flow
Despite operating cash improvement, continued negative free cash flow means investments outpace internally generated cash. Over the medium term this can force reliance on external financing or equity raises, constrain capital allocation to marketing or capacity expansion, and increase dilution or leverage risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage and solid balance sheet
A moderate debt-to-equity (~0.26) and a sizeable equity base provide durable financial flexibility. That leverage profile lowers refinancing and interest risk, helping the company fund vaccine R&D, maintain production capacity and absorb demand swings without immediate recourse to dilutive financing.
Read all positive factors
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.51B
Dividend YieldN/A
Average Volume (3M)609.75K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth31.39%
EPS Growth98.96%
CountryHK
Employees1,105
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$1.43B
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola vir...
How the Company Makes Money
CanSino Biologics primarily makes money by selling vaccines and related biological products. Its revenue model is centered on: (1) commercial sales of approved vaccines to customers such as public health authorities and/or healthcare distribution ...
CanSino Biologics, Inc. Class H Financial Statement Overview
Summary
Income Statement
43
Neutral
Balance Sheet
71
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 1.03B | 846.34M | 345.18M | 1.03B | 4.30B |
| Gross Profit | 826.36M | 681.82M | 601.91M | -876.02M | -186.61M | 3.00B |
| EBITDA | -9.45M | 60.98M | -134.84M | -1.65B | -1.32B | 1.85B |
| Net Income | -848.43K | 27.15M | -378.88M | -1.48B | -909.43M | 1.91B |
Balance Sheet | ||||||
| Total Assets | 6.97B | 7.18B | 7.96B | 9.32B | 11.47B | 11.87B |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 2.65B | 3.20B | 4.12B | 5.95B | 7.78B |
| Total Debt | 1.16B | 1.29B | 2.01B | 2.70B | 2.70B | 1.37B |
| Total Liabilities | 2.06B | 2.05B | 3.05B | 4.03B | 4.22B | 3.33B |
| Stockholders Equity | 4.91B | 4.96B | 4.91B | 5.27B | 6.75B | 8.00B |
Cash Flow | ||||||
| Free Cash Flow | -137.42M | -152.83M | -626.42M | -1.53B | -2.96B | 811.42M |
| Operating Cash Flow | 71.31M | 32.49M | -168.79M | -916.25M | -1.89B | 2.01B |
| Investing Cash Flow | 683.42M | 355.36M | 3.96M | -449.65M | -1.19B | -2.53B |
| Financing Cash Flow | -855.48M | -703.03M | -334.18M | -7.58M | 854.60M | 1.56B |
CanSino Biologics, Inc. Class H Technical Analysis
Negative
44.94
Price Trends
31.32
Negative
33.27
Negative
39.55
Negative
Market Momentum
-1.40
Positive
30.74
Neutral
3.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Negative. The current price of 44.94 is above the 20-day moving average (MA) of 28.50, above the 50-day MA of 31.32, and above the 200-day MA of 39.55, indicating a bearish trend. The MACD of -1.40 indicates Positive momentum. The RSI at 30.74 is Neutral, neither overbought nor oversold. The STOCH value of 3.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6185.
CanSino Biologics, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$28.82B | 13.56 | 13.95% | 4.09% | 1.48% | -1.55% | |
72 Outperform | HK$204.97B | 29.35 | 16.71% | 0.97% | 22.62% | 26.23% | |
58 Neutral | HK$66.40B | 17.27 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$29.59B | 6.50 | 7.98% | 2.95% | 4.66% | 20.76% | |
56 Neutral | HK$38.43B | 11.78 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$11.51B | -14,219.07 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:6185
CanSino Biologics, Inc. Class H
25.46
-8.34
-24.67%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
15.25
-1.36
-8.21%
HK:1513
Livzon Pharmaceutical Group
26.44
-1.55
-5.52%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.54
0.42
2.58%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.62
-0.45
-8.82%
HK:3692
Hansoh Pharmaceutical Group Company Limited
31.40
5.84
22.85%
CanSino Biologics, Inc. Class H Corporate Events
CanSino Launches First-in-Class 24-Valent Pneumococcal Vaccine Trial
May 26, 2026
CanSino Biologics Inc. has initiated a Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine, PCV24, and completed enrollment of the first patient. The vaccine uses dual carrier and covalent conjugation technolo...
CanSino Biologics Sets 2025 AGM With Broad Capital and Governance Mandates on Agenda
May 19, 2026
CanSino Biologics Inc. has convened its 2025 annual general meeting for June 10, 2026 in Tianjin, where shareholders will review the 2025 board work report, annual results and profit distribution plan, as well as adopt a three-year dividend and re...
CanSino Wins Priority Review for First Adult DTaP Booster in China
May 11, 2026
CanSino Biologics said China’s Center for Drug Evaluation under the National Medical Products Administration has granted priority review status to its new drug application for a tetanus, reduced diphtheria and acellular pertussis five-compon...
CanSino Biologics Q1 2026 Revenue Rises but Loss Widens
Apr 28, 2026
CanSino Biologics Inc. reported unaudited results for the first quarter ended March 31, 2026, showing operating revenue of RMB 190.3 million, up 38.7% year-on-year, but a widened net loss attributable to shareholders of RMB 40.4 million. The compa...
CanSino Biologics Tightens Governance With Proposed Articles and Board Rule Changes
Apr 28, 2026
CanSino Biologics Inc. has approved proposed amendments to its Articles of Association and internal rules of procedure, aligning its corporate governance framework with the latest requirements of China’s Company Law and listed company govern...
CanSino Biologics Sets April 28 Board Meeting to Approve Q1 2026 Results
Apr 16, 2026
CanSino Biologics Inc. has scheduled a board meeting for April 28, 2026, to review and approve the company’s first-quarter results for the period ended March 31, 2026. The board will also consider the release of these quarterly figures, sign...
CanSino Wins China Approval for First DTcP Components Infant Vaccine
Apr 12, 2026
CanSino Biologics has received approval from China’s National Medical Products Administration for its DTcP Infant vaccine, a diphtheria, tetanus and acellular pertussis (three components) combined vaccine for children under two, marketed as ...
CanSino Biologics Publishes Audited 2025 Annual Results and Readies Full Report
Mar 30, 2026
CanSino Biologics Inc. has released its audited consolidated annual results for the year ended December 31, 2025, fulfilling disclosure requirements of the Hong Kong Stock Exchange for preliminary annual results announcements. The full annual repo...
CanSino Biologics Sets March 30 Board Meeting to Approve 2025 Results
Mar 17, 2026
CanSino Biologics Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual financial results of the company and its subsidiaries for the year ended December 31, 2025. The board will also consider the publication of th...
CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines
Mar 5, 2026
CanSino Biologics Inc. has obtained a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for the manufacturing site of its ACYW135 meningococcal conjugate vaccine and 13-valent pneumococcal conjugate va...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.